**Question:** In which of the following conditions is the synthesis of hepcidin not reduced?

A. Iron deficiency anemia
B. Sickle cell anemia
C. Chronic kidney disease
D. Chronic liver disease

**Core Concept:**
Hepcidin is a hormone produced by the liver and plays a crucial role in regulating iron homeostasis in the body. Its primary function is to inhibit iron release from macrophages and enterocytes, thereby reducing iron availability for usage by pathogens and other tissues. In conditions where hepcidin is reduced, iron overload occurs.

**Why the Correct Answer is Right:**
In this question, we are interested in conditions where the synthesis of hepcidin is not reduced. Hepcidin is reduced in iron deficiency anemia (Option A) because iron levels are low, leading to the liver producing more hepcidin to prevent iron loss. In contrast, sickle cell anemia (Option B) and chronic kidney disease (Option C), hepcidin is also reduced due to increased hepcidin production by the liver in response to inflammation or anaemia-inducing factors. In chronic liver disease (Option D), hepcidin levels may be reduced or elevated depending on the stage and cause of liver disease.

**Why Each Wrong Option is Incorrect:**
In sickle cell anemia, hepcidin is reduced because of the underlying genetic mutation and its associated anaemia. In chronic kidney disease, hepcidin is reduced due to anemia and inflammation. Chronic liver disease can lead to reduced hepcidin levels, but this may not always be the case.

**Clinical Pearl:**
Understanding the regulation of hepcidin is crucial for managing anemia and other iron-related disorders. In cases where hepcidin is reduced (e.g., in iron deficiency anemia), iron supplementation may be necessary to prevent or treat iron deficiency. In cases where hepcidin is elevated (e.g., in chronic liver disease), iron overload can occur, which is associated with adverse outcomes.

**Correct Answer:** D. Chronic liver disease

In chronic liver disease, the synthesis of hepcidin is influenced by the stage and cause of liver disease. While hepcidin reduction is common in acute liver disease due to increased ferroportin degradation, chronic liver disease can result in increased hepcidin production as well. This increased hepcidin levels inhibit iron export from macrophages, leading to decreased iron availability for erythropoiesis and anemia development. Consequently, reducing hepcidin levels can be beneficial in managing anemia associated with chronic liver disease.